• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病的流行病学与自然史
J Clin Exp Hepatol. 2012 Jun;2(2):135-44. doi: 10.1016/S0973-6883(12)60102-9. Epub 2012 Jul 21.
2
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.系统评价:成人非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学和自然史。
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.
3
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌:日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
4
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
5
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
6
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
7
Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的诊断与分类:当前概念与尚存挑战
Hepatol Res. 2015 Jan;45(1):20-8. doi: 10.1111/hepr.12333. Epub 2014 May 20.
8
Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature.南亚人群中的非酒精性脂肪性肝病:文献综述
J Clin Transl Hepatol. 2017 Mar 28;5(1):76-81. doi: 10.14218/JCTH.2016.00045. Epub 2017 Feb 7.
9
The epidemiology of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的流行病学。
Liver Int. 2017 Jan;37 Suppl 1:81-84. doi: 10.1111/liv.13299.
10
Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.日本非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学:文献综述
JGH Open. 2020 May 5;4(5):808-817. doi: 10.1002/jgh3.12349. eCollection 2020 Oct.

引用本文的文献

1
Exploring the Impact of Physical Activity on Cryptogenic Steatotic Liver Disease: A Nigerian Case-Control Study.探究体育活动对隐源性脂肪性肝病的影响:一项尼日利亚病例对照研究。
Niger Med J. 2025 Jun 16;66(2):754-760. doi: 10.71480/nmj.v66i2.794. eCollection 2025 Mar-Apr.
2
Impact of metabolic-associated fatty liver disease on the cholesterol efflux capacity of high-density lipoproteins in adolescents with type 2 diabetes.代谢相关脂肪性肝病对2型糖尿病青少年高密度脂蛋白胆固醇流出能力的影响。
Front Pediatr. 2024 Dec 24;12:1462406. doi: 10.3389/fped.2024.1462406. eCollection 2024.
3
Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects.机遇与挑战:白细胞介素-22 从代谢和免疫方面全面调节多囊卵巢综合征。
J Ovarian Res. 2023 Jul 31;16(1):149. doi: 10.1186/s13048-023-01236-9.
4
Insulin Resistance Is the Main Characteristic of Metabolically Unhealthy Obesity (MUO) Associated with NASH in Patients Undergoing Bariatric Surgery.胰岛素抵抗是接受减肥手术患者中与非酒精性脂肪性肝炎相关的代谢不健康肥胖(MUO)的主要特征。
Biomedicines. 2023 May 31;11(6):1595. doi: 10.3390/biomedicines11061595.
5
Alcoholic vs. Nonalcoholic Steatohepatitis: Vascular Branching Heterogeneity on Magnetic Resonance Imaging as a Diagnostic Marker.酒精性与非酒精性脂肪性肝炎:磁共振成像上的血管分支异质性作为一种诊断标志物
J Clin Transl Hepatol. 2023 Jun 28;11(3):534-539. doi: 10.14218/JCTH.2022.00279. Epub 2023 Jan 10.
6
The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019.204 个国家和地区非酒精性脂肪性肝病的全球、区域和国家负担及趋势:基于 2019 年全球疾病负担研究的分析。
JMIR Public Health Surveill. 2022 Dec 12;8(12):e34809. doi: 10.2196/34809.
7
CD4 T cell activation and inflammation in NASH-related fibrosis.CD4 T 细胞激活和 NASH 相关纤维化中的炎症反应。
Front Immunol. 2022 Aug 10;13:967410. doi: 10.3389/fimmu.2022.967410. eCollection 2022.
8
Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.多囊卵巢综合征分子靶点及基于表观遗传学的治疗进展
Reprod Sci. 2023 Mar;30(3):772-786. doi: 10.1007/s43032-022-01013-x. Epub 2022 Jun 28.
9
The Translational Bridge between Inflammation and Hepatocarcinogenesis.炎症与肝癌发生的转化桥梁。
Cells. 2022 Feb 3;11(3):533. doi: 10.3390/cells11030533.
10
Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data.饮食因素对非酒精性脂肪性肝病肝死亡率的影响:全球疾病负担数据。
Hepatol Commun. 2022 Jan;6(1):90-100. doi: 10.1002/hep4.1707. Epub 2021 Jul 8.

本文引用的文献

1
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.非酒精性脂肪性肝病的诊断与管理:美国肝病研究协会、美国胃肠病学会和美国胃肠病协会实践指南
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
2
Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review.与非酒精性脂肪性肝病的存在和进展相关的遗传因素:一项叙述性综述。
Gastroenterol Hepatol. 2012 Jan;35(1):32-41. doi: 10.1016/j.gastrohep.2011.08.002. Epub 2011 Nov 16.
3
Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy.非酒精性脂肪性肝病:疾病谱、诊断和治疗的综述。
Nutr Clin Pract. 2011 Oct;26(5):565-76. doi: 10.1177/0884533611419668.
4
Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中从单纯性肝脂肪变性进展为脂肪性肝炎和肝纤维化。
Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):23-8. doi: 10.1016/j.gcb.2010.06.004.
5
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.系统评价:成人非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学和自然史。
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.
6
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.美国 1988 年至 2008 年最常见慢性肝病病因的流行率变化。
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25.
7
Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.非酒精性脂肪性肝病(NAFLD):为何你应该关心,何时你应该担忧,你应该怎么做。
Diabetes Metab Res Rev. 2011 Jul;27(5):419-24. doi: 10.1002/dmrr.1198.
8
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.全基因组关联分析鉴定出与非酒精性脂肪性肝病相关的变异,这些变异对代谢特征有不同的影响。
PLoS Genet. 2011 Mar;7(3):e1001324. doi: 10.1371/journal.pgen.1001324. Epub 2011 Mar 10.
9
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.非酒精性脂肪性肝炎的病理诊断标准:方案间一致性和预测肝相关死亡率的能力。
Hepatology. 2011 Jun;53(6):1874-82. doi: 10.1002/hep.24268. Epub 2011 May 14.
10
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).多囊卵巢综合征(PCOS)患者的非酒精性脂肪性肝炎(NASH)。
Scand J Gastroenterol. 2011 Apr;46(4):479-84. doi: 10.3109/00365521.2010.539251. Epub 2010 Nov 30.

非酒精性脂肪性肝病的流行病学与自然史

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.

作者信息

Mishra Alita, Younossi Zobair M

机构信息

Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.

Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA ; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

出版信息

J Clin Exp Hepatol. 2012 Jun;2(2):135-44. doi: 10.1016/S0973-6883(12)60102-9. Epub 2012 Jul 21.

DOI:10.1016/S0973-6883(12)60102-9
PMID:25755422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3940561/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease burden across the world. By definition, although the histopathologic features of NAFLD are identical to that of alcoholic liver disease, its diagnosis requires absence of significant alcohol use and absence of other causes of chronic liver disease. We now know that NAFLD is not simply a disease of the Western world. It is manifested across the world, in varying rates, across gender, across varying ethnicities, and in its association with other host factors. In this review article, the definition of NAFLD, its spectrum, ranging from mild steatosis to hepatocellular injury and inflammation defined as non-alcoholic steatohepatitis (NASH) is discussed. Mild steatosis is generally a stable disease whereas NASH can be progressive. Based on current published literature, current incidence and prevalence of NAFLD and NASH are discussed. It is also accepted that these processes will continue to increase in prevalence with the rise of obesity, type II diabetes, and associated metabolic syndrome. Some of the risk factors have been well-established and are discussed. In addition, this review also presents emerging associations with other risk factors for NAFLD. Natural history of NAFLD is variable depending upon the histologic subtypes and other underlying comorbidities and is discussed in this review as well.

摘要

非酒精性脂肪性肝病(NAFLD)是全球肝脏疾病负担的一个重要原因。根据定义,尽管NAFLD的组织病理学特征与酒精性肝病相同,但其诊断需要排除大量饮酒以及其他慢性肝病病因。我们现在知道,NAFLD并非仅仅是西方世界的疾病。它在全球范围内均有表现,在不同性别、不同种族中发病率各异,且与其他宿主因素相关。在这篇综述文章中,我们将讨论NAFLD的定义、其范围,从轻度脂肪变性到肝细胞损伤以及被定义为非酒精性脂肪性肝炎(NASH)的炎症。轻度脂肪变性通常是一种稳定的疾病,而NASH可能会进展。基于当前已发表的文献,我们将讨论NAFLD和NASH的当前发病率及患病率。人们也普遍认为,随着肥胖症、2型糖尿病以及相关代谢综合征发病率的上升,这些疾病的患病率也将持续增加。一些风险因素已经明确并在文中进行了讨论。此外,本综述还介绍了与NAFLD其他风险因素的新关联。NAFLD的自然病程因组织学亚型和其他潜在合并症而异,本文也将对此进行讨论。